TW202408500A - 血中ldl膽固醇降低劑 - Google Patents
血中ldl膽固醇降低劑 Download PDFInfo
- Publication number
- TW202408500A TW202408500A TW112126331A TW112126331A TW202408500A TW 202408500 A TW202408500 A TW 202408500A TW 112126331 A TW112126331 A TW 112126331A TW 112126331 A TW112126331 A TW 112126331A TW 202408500 A TW202408500 A TW 202408500A
- Authority
- TW
- Taiwan
- Prior art keywords
- blood
- ldl
- statins
- administration
- blood ldl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022-113930 | 2022-07-15 | ||
| JP2022113930 | 2022-07-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202408500A true TW202408500A (zh) | 2024-03-01 |
Family
ID=89536850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW112126331A TW202408500A (zh) | 2022-07-15 | 2023-07-14 | 血中ldl膽固醇降低劑 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20260014122A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4556006A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2024014524A1 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250034041A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119546300A (cg-RX-API-DMAC7.html) |
| JO (1) | JOP20250007A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202408500A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2024014524A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20110009T1 (hr) | 2003-09-03 | 2011-03-31 | Kowa Co. | Spoj kojim se aktivira ppar i farmaceutski pripravak koji ga sadrži |
| TWI696462B (zh) * | 2013-07-10 | 2020-06-21 | 日商興和股份有限公司 | 非酒精性脂肪性肝疾病治療劑 |
| PT3275438T (pt) * | 2016-07-29 | 2021-01-25 | Kowa Co | Métodos de prevenção de eventos cardiovasculares em populações dislipidémicas de risco residual |
| US11446282B2 (en) * | 2017-12-21 | 2022-09-20 | Kowa Company, Ltd. | Methods of treating mixed dyslipidemia and hypertriglycertdemia |
| CA3085951C (en) * | 2017-12-21 | 2022-10-11 | Kowa Company, Ltd. | Methods of treatment of hypertriglyceridemia |
| EP4346809B1 (en) * | 2021-05-27 | 2026-07-15 | Kowa Company, Ltd. | Pemafibrate for use in treating liver disease |
-
2023
- 2023-07-14 JP JP2024533757A patent/JPWO2024014524A1/ja active Pending
- 2023-07-14 US US18/880,136 patent/US20260014122A1/en active Pending
- 2023-07-14 WO PCT/JP2023/025980 patent/WO2024014524A1/ja not_active Ceased
- 2023-07-14 TW TW112126331A patent/TW202408500A/zh unknown
- 2023-07-14 CN CN202380054016.8A patent/CN119546300A/zh active Pending
- 2023-07-14 EP EP23839693.1A patent/EP4556006A4/en active Pending
- 2023-07-14 KR KR1020247043248A patent/KR20250034041A/ko active Pending
-
2025
- 2025-01-13 JO JOJO/P/2025/0007A patent/JOP20250007A1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4556006A1 (en) | 2025-05-21 |
| KR20250034041A (ko) | 2025-03-10 |
| JOP20250007A1 (ar) | 2025-01-13 |
| EP4556006A4 (en) | 2026-01-07 |
| CN119546300A (zh) | 2025-02-28 |
| JPWO2024014524A1 (cg-RX-API-DMAC7.html) | 2024-01-18 |
| US20260014122A1 (en) | 2026-01-15 |
| WO2024014524A1 (ja) | 2024-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10632112B2 (en) | Combination therapy for treatment of HBV infections | |
| EP1353696B1 (en) | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications | |
| US12042483B2 (en) | Prophylactic and therapeutic drug for nonalcoholic fatty liver disease | |
| TW200306853A (en) | Therapeutic agent for glomerular disease | |
| Baetz et al. | A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours | |
| KR20250034041A (ko) | 혈중 ldl 콜레스테롤 저하제 | |
| US20210322376A1 (en) | Methods for reducing the risk of diabetes in patients being treated for high cholesterol-related illnesses | |
| JP6454436B1 (ja) | ペマフィブラートを含有する医薬 | |
| JP2024532129A5 (cg-RX-API-DMAC7.html) | ||
| WO2001034134A2 (en) | Oncolytic combinations for the treatment of cancer | |
| WO2004096276A9 (ja) | 糖取り込み能増強剤 | |
| CN112451678B (zh) | HMG-CoA还原酶抑制剂-维D的药物组合物及用途 | |
| WO2022224962A1 (ja) | 脂質異常症又は心臓血管病の予防・治療のための組合せ医薬 | |
| TW202408499A (zh) | 降低血中肌肉生長抑制素之藥劑 | |
| KR20240168338A (ko) | 호흡기 질환 치료제 | |
| US10576101B2 (en) | Roneparstat combined therapy of multiple myeloma | |
| CN101534825A (zh) | 含有贝特类药物的制剂及其制备方法 | |
| CZ20023459A3 (cs) | Antihypertensní činidla a jejich použití | |
| JP2005533851A (ja) | 高コレステロール血症処置用物質および方法 | |
| OA20813A (en) | Methods of administering voxelotor | |
| WO2006090756A1 (ja) | 脂質代謝異常、肥満および糖尿病の新規な予防または治療剤およびそのための使用 | |
| JP2007308484A (ja) | 高脂血症の予防及び/又は治療のための医薬 | |
| HK1056696B (en) | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |